Current position:Product center > Cell lines > TAA > SLC39A6
SLC39A6
Background

     

LIV-1 (also known as SLC39A6 or ZIP6) belongs to the zinc transporter protein SLC39A family, which consists of 14 family members divided into four subfamilies: ZIP-I (ZIP9), ZIP-II (ZIP1-3), gufA (ZIP11), and LIV-1 (ZIP4-8, ZIP10, ZIP12-14). All SLC39A transporter proteins have 5 to 8 transmembrane domains and function in zinc ion transport.


SLC39A6 has been shown to promote the nuclear translocation of the transcription factor Snail, a inducer of epithelial-mesenchymal transition (EMT), recognized as a downstream target of the STAT3 pathway in zebrafish gastrula tissues. Based on structural similarity, SLC39A6 may act as a zinc influx transporter protein. Studies demonstrate that SLC39A6 is induced by histone deacetylase inhibitors in tumors, playing a role in apoptotic cell death induced by histone deacetylase inhibitors. SLC39A6 is also considered a key mediator for the survival of breast cancer cells under high glucose conditions.

SLC39A6-2.png

Products
SLC39A6 Expression Cell Line
Cat. No. Product Stock
GM-C13340
H_SLC39A6 HEK-293 Cell Line
In-stock
GM-C13341
H_SLC39A6 CHO-K1 Cell Line
In-stock
GM-C25070
H_SLC39A6 LLC1 Cell Line
In-stock
GM-C32904
H_SLC39A6 MC38 Cell Line
In-stock
GM-C15382
Cynomolgus_SLC39A6 CHO-K1 Cell Line
In-stock
Current position:Product Center > Cell lines > TAA > SLC39A6
classify
SLC39A6
Background

T cell immunotherapy typically targets two classes of antigens: private antigens and public antigens. Public antigens are those shared among multiple patients, with tumor-associated antigens (TAAs) being antigens that are highly expressed in tumor cells and present in healthy cells but at lower levels. 

Targeted therapy against TAAs is a crucial approach in cancer treatment, with several immunotherapy drugs relying on this mechanism proving to be very effective clinically. The development of drugs targeting TAAs remains an active area of research, with numerous targeted drugs for different types of tumors currently undergoing preclinical or clinical testing. Antibodies targeting TAAs can not only directly kill tumor cells through ADCC effects but also serve as diagnostic markers or innovative additions to traditional cancer therapies.TAA-2.png

Product List
SLC39A6 Expression Cell Line
Cat. No. Product Stock
GM-C15382
Cynomolgus_SLC39A6 CHO-K1 Cell Line
In-stock
GM-C15382
Cynomolgus_SLC39A6 CHO-K1 Cell Line
In-stock
GM-C15382
Cynomolgus_SLC39A6 CHO-K1 Cell Line
In-stock
GM-C15382
Cynomolgus_SLC39A6 CHO-K1 Cell Line
In-stock
GM-C15382
Cynomolgus_SLC39A6 CHO-K1 Cell Line
In-stock
Tel: 400-627-9288
Message consultation
reset
submit
Service
WhatApp
Phone
Message
Message consultation
reset
submit